Arzerra sales give Genmab USD 5.76 million
The Danish antibody company receives a royalty payment of USD 5.76m from partner GlaxoSmithKline for Q3 sales of a popular leukemia drug. Although the payment is the same as the previous quarter, sales of the drug have improved.
by Benjamin Werner Christensen
One of Genmab’s most important products, leukemia drug Arzerra (ofatumumab), sold for a total of GBP 17.8m, or about USD 28.8m, in Q3 2013. Genmab’s licensing deal with partner GSK, meaning that Genmab receives royalties of at least 20 % from the sale of the drug, provides for a payment of about USD 5.76m for the Danish company for the quarter, Genmab reveals in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Analyst: Next sclerosis trigger awaits
For abonnenter
Genmab chief: Morale is sky high
For abonnenter
